Aderibigbe Y A, Mathews T
Dayton VAMC/Wright State University School of Medicine, Ohio, USA.
Clin Neuropharmacol. 1999 May-Jun;22(3):151-8.
The authors reviewed the trends in the incidence of neuroleptic malignant syndrome (NMS) in studies recently reported in various countries. Possible reasons for the differences in reported incidences were considered. The authors identified publications in English (and their cross-references) that estimated the incidence of NMS with a retrospective or prospective design. They compared the incidence in studies from the United States with those from other countries. The initial retrospective studies from the United States reported higher incidence rates of NMS than did similar studies from elsewhere. More recent prospective studies from the United States report a much lower incidence. Neuroleptic malignant syndrome remains a rare complication of psychotropic treatment if the syndrome is defined stringently. The high incidence reported in earlier studies in the United States can be explained by retrospective study design, loose diagnostic criteria, adherence to an amorphous "spectrum concept," and clinical practices in vogue.
作者回顾了各国近期报道的研究中抗精神病药恶性综合征（NMS）的发病率趋势。分析了报道发病率存在差异的可能原因。作者检索了英文出版物（及其参考文献），这些文献采用回顾性或前瞻性设计估算了NMS的发病率。他们比较了美国研究与其他国家研究中的发病率。美国最初的回顾性研究报道的NMS发病率高于其他地方的类似研究。美国最近的前瞻性研究报道的发病率则低得多。如果严格定义该综合征，抗精神病药恶性综合征仍然是精神药物治疗中一种罕见的并发症。美国早期研究中报道的高发病率可以通过回顾性研究设计、宽松的诊断标准、对模糊的“谱系概念”的坚持以及当时流行的临床实践来解释。
